CAR-T细胞治疗消化系统肿瘤的研究进展

The research progress of CAR-T therapy in the malignant tumors of digestive system

消化系统肿瘤具有高发病率、高病死率的特点,在我国的肿瘤谱中,消化系统肿瘤占一半以上。对于消化系统肿瘤,目前最有效的手段仍然是手术,但是一旦缺乏手术指征,就几乎没有特别有效的治疗手段。因此,亟需发展新型的治疗手段。嵌合抗原受体修饰的T细胞(CAR-T)无疑是最令人期待的治疗手段之一,目前已经有多个针对消化系统肿瘤的临床试验正在开展。最近,个别方案已经取得了令人兴奋的临床研究结果。将对最新进展作一简要综述。

Malignant tumors of digestive system present with high morbidity and mortality.In China,these tumors occupy over 50% percent of the whole tumor spectrum.As for malignant tumors of digestive system,surgery is often the best treatment option.However,once the lack of surgical indications,almost no highly effective treatments are available.Therefore,novel treatment modalities are urgent needs.Chimeric antigen receptor-engineered T cells（CAR-T） undoubtedly are one of the most promising therapies for the malignant tumors of digestive system.Currently,several clinical trials using CAR-T cells to treat tumors of digestive system are under performed.And some of them have shown promising clinical outcome.Here,we will give a brief review on the recent progress about CAR-T in the treatment of tumors of digestive system.